NEW YORK, July 3, 2026 – SL Science Holding Limited (NASDAQ: SLBT) made a striking debut on the Nasdaq, with shares closing Tuesday at $5.99, a 34.6% gain from its prior session. The stock traded between $4.30 and $6.25, with volume reaching 1.22 million shares. The Nasdaq will be closed Friday for the Independence Day holiday, so the next trading session for SLBT is Monday, July 6.
The company's market capitalization now stands at approximately $3.36 billion, a figure that sharply contrasts with its expected 2025 revenue of just $2.197 million. This implies a valuation multiple of roughly 1,529 times sales, a level that typically raises eyebrows among value-focused investors. The stock has surged 59.7% over the past five trading sessions, according to WSJ/FactSet data.
Valuation Metrics Raise Questions
SL Science's financials reveal a significant gap between market perception and underlying business performance. The company reported a 35% decline in 2025 revenue to $2.197 million, while its net loss widened to $3.821 million. Cash and restricted cash at year-end totaled only $1.26 million. The market cap is approximately 2,667 times the cash on hand, and 431 times the $7.8 million PIPE financing that closed as part of its merger with Horizon Space Acquisition II Corp. (NASDAQ: HSPT).
Despite the lack of revenue from its core CD-19 Armed-T or GDT cell therapy units in 2025—sales came solely from exosome products—the company's implied equity value from the June merger was $5.568 billion. The current market cap is about 60.3% of that figure, suggesting the stock has already priced in substantial future growth.
Market Context and Analyst Coverage
The broader market provided a mixed backdrop for SLBT's debut. The Dow Jones Industrial Average added 1.1%, while the S&P 500 was little changed and the Nasdaq slipped 0.8%. Speculative healthcare stocks gained some traction, supported by a weak jobs report that eased pressure on the Federal Reserve to raise rates, according to Adam Sarhan, CEO of 50 Park Investments.
Despite the stock's volatility, public price target data remains unavailable. Google Finance reports no analyst ratings, and WSJ/FactSet similarly show no analyst targets or ratings for the stock, leaving investors without professional guidance on fair value.
Company Outlook and Milestones
Chairman and CEO William Wang has outlined a strategic shift toward therapeutic development, moving from retail sales to corporate distribution. The company expects a Pre-IND meeting and an IND filing for CD-19 Armed-T in the first quarter of 2027, with its GDT platform aiming for an IND in the third quarter of 2027. Wang emphasized a focus on “standardization and scalable manufacturing” for cell therapy, as reported by GlobeNewswire.
The merger with Horizon Space Acquisition II Corp. was completed in June, with Horizon's shares, rights, and units halted on Nasdaq starting June 15. SLBT took over as the listed entity, and holders received one SLBT share for each Horizon share and one SLBT share for every 10 rights.
As the market digests these developments, SLBT's extreme valuation premium and lack of near-term revenue catalysts suggest a high-risk profile. The stock remains 58.7% below its 52-week high of $14.50, according to Google Finance, indicating significant downward pressure from earlier levels.
